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Premature Termination Codon Read-Through in
the ABCC6 Gene: Potential Treatment for
Pseudoxanthoma Elasticum
Yong Zhou1,2,3, Qiujie Jiang1,3, Shunsuke Takahagi1, Changxia Shao1 and Jouni Uitto1
Pseudoxanthoma elasticum (PXE) is an autosomal recessive disorder manifesting with ectopic connective tissue
mineralization, caused by mutations in the ABCC6 gene, with B35% of all mutations being premature
termination mutations. In this study, we investigated the therapeutic potential of the nonsense codon read-
through-inducing drug, PTC124, in treating PXE. The ability of this drug to facilitate read-through of nonsense
mutations was examined in HEK293 cells transfected with human ABCC6 expression constructs harboring seven
different PXE-associated nonsense mutations, and was evaluated by immunofluorescence and In-Cell ELISA. Our
data demonstrated that PTC124 did not exhibit cytotoxicity in concentrations up to 20mgml 1, and the facilitated
read-through varied not only with dose but also with sequence context. Considering the redundancy of the
genetic code, it was postulated that in case of the most common recurrent nonsense mutation, p.R1141X, the
read-through may result in substitution of the arginine 1,141 by glycine, tryptophan, or cysteine. Their potential
pathogenicity was tested in a recently developed zebrafish messenger RNA (mRNA) rescue assay, and
demonstrated that all three mRNA transcripts were able to rescue abcc6a morpholino-induced phenotype of
zebrafish. Thus, our results suggest that read-through of nonsense mutations in ABCC6 by PTC124 may have
potential for pharmacologic treatment of PXE.
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INTRODUCTION
Pseudoxanthoma elasticum (PXE) is a multisystem heritable
disorder characterized by ectopic mineralization in the skin,
eyes, and the vascular systems (Neldner, 1988; Uitto et al.,
2010). The early cutaneous findings consist of yellowish
papules on the predilection sites, i.e., sides of the neck and
antecubital fossae, coalescing into inelastic plaques of
leathery skin that can extend to involve the entire
integument. Although the skin findings are primarily of
cosmetic concern, they signify the possibility of the
development of serious, debilitating, and occasionally life-
threatening complications in the eyes and the cardiovascular
system. The characteristic ophthalmologic finding in patients
with PXE is the presence of angioid streaks, and after the age
of 30 years their prevalence approaches 100%. Angioid
streaks derive from breaks upon aberrant mineralization of
the elastic lamina of Bruch’s membrane, which separates the
pigmented layer of the retina from the choroid of the
eye. These fractures lead to neovascularization from chorio-
capillaris, and subsequent leakage of newly formed vessels
leads to hemorrhage and scarring. These progressive
pathologic changes cause loss of visual acuity and
eventually lead to central blindness if left untreated (Finger
et al., 2009; Georgalas et al., 2011). The cardiovascular
involvement, primarily reflecting mineralization of medium-
sized arterial blood vessels, manifests with hypertension,
intermittent claudication, bleeding from the gastrointestinal
vessels, and, occasionally, myocardial infarcts and strokes.
PXE is caused by mutations in the ABCC6 gene that encodes
a transmembrane efflux transporter protein, ABCC6, expressed
primarily in the liver and the kidneys (Belinsky and Kruh,
1999). The precise function of this protein remains to be
disclosed; however, the critical role of the ABCC6 gene
in the pathogenesis of PXE has been confirmed by the
development of transgenic mice through targeted ablation
of the corresponding mouse gene (Gorgels et al., 2005;
Klement et al., 2005). Over 300 distinct mutations represent-
ing well over 1,000 mutant alleles have so far been encoun-
tered in the ABCC6 gene (http://www.ncbi.nlm.nih.gov/lovd/
home.php?select_db=ABCC6). Although the repertoire of
these distinct mutations is varied, B35% of all mutations
are nonsense mutations that result in the synthesis of
truncated, nonfunctional ABCC6 protein. The most common
ORIGINAL ARTICLE
1Departments of Dermatology and Cutaneous Biology, and Biochemistry and
Molecular Biology, Jefferson Medical College, and Jefferson Institute of
Molecular Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania,
USA and 2Department of Dermatology, Division of Internal Medicine, Chinese
PLA (People’s Liberation Army) General Hospital, Beijing, China
Correspondence: Jouni Uitto and Qiujie Jiang, Department of Dermatology
and Cutaneous Biology, Jefferson Medical College, 233 South 10th Street, Suite
450 BLSB, Philadelphia, Pennsylvania 19107, USA.
E-mail: Jouni.Uitto@jefferson.edu or Qiujie.Jiang@jefferson.edu
3These authors contributed equally to this work.
Received 1 March 2013; revised 17 April 2013; accepted 27 April 2013;
accepted article preview online 23 May 2013; published online 27 June 2013
Abbreviations: mRNA, messenger RNA; PXE, pseudoxanthoma elasticum
2672 Journal of Investigative Dermatology (2013), Volume 133 & 2013 The Society for Investigative Dermatology
recurrent nonsense mutation is p.R1141X, which accounts for
B30% of all pathogenic PXE mutations in Caucasian patient
populations.
Recently, pharmaceutical compounds have been developed
to read through premature termination codons that allow
synthesis of a full-length, potentially functional protein. These
include 1,2,4-oxadiazole, known as PTC124, a nonaminogly-
coside nonsense mutation suppressor (Welch et al., 2007;
Du et al., 2008; Peltz et al., 2013). The pharmacologic safety
of this molecule has already been established, and clinical
trials have been initiated to examine its effectiveness in the
treatment of cystic fibrosis and muscular dystrophy in cases
caused by nonsense mutations (Hirawat et al., 2007; Finkel,
2010; Wilschanski et al., 2011). In this study, we have
examined the efficacy of PTC124 in suppressing a number
of nonsense mutations in the ABCC6 gene.
RESULTS
In vitro assay system for ABCC6 expression
A total of 25 distinct nonsense mutations have been encoun-
tered in the ABCC6 gene in patients with PXE. In this study,
we focused on seven of them, including the most common
stop codon mutation, p.R1141X, in which the arginine at
position 1,141 (codon CGA) has been replaced by a stop
codon (TGA) (Table 1). We first constructed an ABCC6
expression vector by cloning full-length human ABCC6
complementary DNA with a 30-end DDK tag into the
pCMV6-Entry vector. The expression of the full-length ABCC6
protein from this vector was examined by transfecting a
number of different cell lines, including HEK293, NIH3T3,
HeLa, and MLE-10 cells, followed by immunodetection of the
DDK tag at the carboxy terminal end of the newly synthesized
protein using a specific anti-DDK antibody. Although this
vector was readily expressed in a number of cell lines tested,
the best transfection and translation efficiency was noted in
HEK293 cells (a human embryonic kidney epithelial cell line;
Figure 1a). We subsequently tested expression vectors contain-
ing the mutant ABCC6 complementary DNA into which
different premature stop codon mutations were introduced
by site-directed mutagenesis (Table 1). Transfection of the
mutant constructs into HEK293 cells did not show any
evidence of synthesis of full-length protein (Figure 1b),
although the transfection efficiency, as determined by parallel
transfection with a CMV-EGFP construct, was comparable to
that noted with the wild-type construct.
PTC124 induces read-through of nonsense mutations in ABCC6
PTC124, a nonaminoglycoside premature termination codon
suppressor, was then added to the incubation medium of cells
transfected with mutant constructs. First, testing of PTC124 in
different concentrations up to 72 hours of incubation indicated
facilitation of the synthesis of full-length ABCC6 polypeptide,
as determined by immunostaining with an anti-DDK antibody
(Figure 1c and d). Testing of two mutant constructs, p.R1164X
and p.R1275X, in the presence of varying concentrations
of PTC124 indicated that the highest level of expression
was noted with 5mg ml1, as quantified by In-Cell ELISA
(Figure 2). Subsequently, all mutant ABCC6 expression con-
structs were tested for the read-through efficacy of PTC124 at
a concentration of 5mg ml1 at 48 or 72 hours of incubation.
The results indicated varying degrees of enhancement with
different mutant constructs at 48 hours, but in each case the
amount of full-length protein was increased when the incuba-
tion was continued up to 72 hours (Figure 3). Thus, PTC124 is
able to induce the read-through of a number of termination
Table 1. Different pseudoxanthoma elasticum (PXE)–
associated nonsense mutations tested for PTC124
read-through
Mutation
Nucleotide
sequence1
Location
(exon)
Mutation
frequency (%)2
p.R1141X TGA-A 24 54
p.R1164X TGA-C 24 10
p.R518X TGA-G 12 1.2
p.R1398X TGA-G 29 1.2
p.Q378X TAG-A 9 o1
p.Q1143X TAG-G 24 o1
p.R1275X TGA-C 27 o1
1The sequence depicts the stop codon (bold) followed by the nucleotide
shown.
2Frequency of the mutations in the ABCC6 mutation database (http://
www.ncbi.nlm.nih.gov/lovd/home.php?select_db¼ABCC6) as percent of
all nonsense mutations (total of 25 different mutations).
Figure 1. Expression of wild-type and mutant human ABCC6 complementary
DNA (cDNA), and demonstration that PTC124 induces read-through of a stop
codon. An expression vector (p.CMV6-Entry) containing full-length wild-type
human ABCC6 cDNA (a) or a corresponding mutant cDNA harboring
p.R1141X premature termination codon containing a 30-end sequence that
encodes a DDK reporter peptide (b, c) or p.R1275X (d) was transfected into
HEK293 cells in culture without (a, b) or with PTC124 (10mg ml 1 for
72 hours) (c, d). The cell cultures were then stained with an anti-DDK antibody
for the expression of full-length polypeptide.
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codon mutations in ABCC6 in a time-dependent manner, but
the degree of enhancement appears to be context dependent,
influenced by the precise nucleotide sequence of the stop
codon and the immediate 30 nucleotide present in the
sequence (Howard et al., 2000; Rowe and Clancy, 2009).
As PTC124 was more efficient in inducing the read-through
at 5mg ml 1 than at 10 or 20mg ml1 concentration, subse-
quent experiments were performed to examine the toxicity
of PTC124 in cell culture at different concentrations
(0–100mg ml1) up to 72 hours of incubation. The viability
of HEK293 cells was determined by MTT colorimetric assay.
The results indicated that PTC124 at concentrations of
0–20mg ml1 did not affect the viability of the cells in
comparison with cells incubated with the vehicle
(DMSO). At concentrations over 40mg ml 1, PTC124 elicited
a statistically significant reduction of cell viability (Po0.05;
Figure 4).
A zebrafish system to test the functionality of ABCC6
polypeptides
Although the precise mechanisms of PTC124 in facilitating
read-through of stop codon mutations in the ABCC6 gene are
currently unknown, it apparently replaces the stop codon with
another amino acid through the mispairing of a near-cognate
aminoacyl transfer RNA (Nilsson and Ryden-Aulin, 2003).
In case of the p.R1141X mutation, considering the codon
redundancy and possible combinations of the corrected
mutations from the stop codon (TGA) to an amino acid, in
addition to arginine (CGA), this position could be occupied
either by cysteine (TGC) or tryptophan (TGG) or glycine
(GGA). As a number of missense mutations have also
been encountered in ABCC6 in patients with PXE, there is a
possibility, at least theoretical, that the full-length polypeptide
synthesized in the presence of PTC124 is nonfunctional.
To test the functionality of the full-length ABCC6 protein
synthesized in the presence of PTC124, which instead of an
arginine in position 1,141 contains cysteine, tryptophan, or
glycine, we used a zebrafish messenger RNA (mRNA) rescue
system recently developed by us (Li et al., 2011). In this
system, injection of 1- to 4-cell-stage zebrafish embryos with a
morpholino corresponding to the exon 7/intron 7 border of the
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Figure 2. Read-through efficiency of stop codon mutations p.R1275X and
p.R1164X by PTC124 in different concentrations. HEK293 cells were
transfected with expression vectors containing full-length human ABCC6
complementary DNA (cDNA) harboring one of the two nonsense mutations.
The cells were placed on medium containing PTC124 in concentrations
indicated, and the read-through of full-length polypeptide was quantified by an
In-Cell ELISA with an anti-DDK antibody. The values represent determinations
from three independent cultures (mean±SEM). OD, optical density.
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Figure 3. Read-through efficiency of different nonsense mutations by PTC124
(5lg ml1) at 48 and 72 hours of incubation. HEK293 cells were transfected
with the mutant expression vectors as indicated in the legend to Figure 2.
The nucleotide sequences of the stop codon mutations are shown in Table 1.
The expression of full-length polypeptide was quantified by an In-Cell ELISA.
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Figure 4. Demonstration that PTC124 is not toxic to the cells in culture
up to 20lg ml 1. HEK293 cells were incubated for 72 hours with varying
concentrations of PTC124, and the viability of cells was determined by MTT
colorimetric assay. PTC124 in the concentration range of 0–20mg ml 1 did not
affect the viability of the cells after normalization to the viability of cells
incubated with the corresponding concentration of vehicle (DMSO) in
parallel. At concentrations of 40, 60, and 100mg ml 1, PTC124 elicited a
statistically significant reduction of cell viability (*Po0.05; Student’s t-test;
mean±SEM; n¼3).
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abcc6a gene decreases the gene expression by up to 80% and
induces a phenotype of pericardial edema and curled tail
associated with early demise. Microinjecting the embryos
with full-length human ABCC6 mRNA together with the
morpholino rescues this phenotype (Figure 5). In contrast,
injection of human ABCC6 mRNA harboring the p.R1141X
stop codon mutation failed to reverse the phenotype
(Figure 5d and Table 2), suggesting that this mRNA rescue
system can be used to check the pathogenicity of mutant
human ABCC6 proteins, including those harboring the mis-
sense amino acids as a result of PTC124 read-through. We
therefore engineered mutant human ABCC6 constructs that
encode either cysteine or tryptophan or glycine in position
1,141 using a site-directed mutagenesis kit, and these mutant
mRNAs were injected into zebrafish embryos in parallel to
wild-type mRNA containing arginine in the corresponding
position. Quantification of embryonic lethality allowed us to
determine whether the read-through ABCC6 protein is func-
tional or not in rescuing the zebrafish phenotype. The results
indicated that the lethality of the embryos injected with the
abcc6a morpholino at day 1 after fertilization wasB70%, but
this was reversed to the control level (B10–12%) by the
human wild-type mRNA harboring arginine at position 1,141
or as noted in embryos injected with universal standard
control morpholino (Table 2). Similarly, the constructs harbor-
ing either cysteine or tryptophan or glycine in place of
arginine reversed the morpholino-induced lethality (Figure 5
and Table 2).
DISCUSSION
The overall goal of this study is to develop a pharmacologic
treatment for a subset of patients with PXE, viz., those
harboring nonsense mutations in one or both ABCC6 alleles.
Our data, which demonstrated read-through of a stop codon
in the presence of PTC124, attest to the feasibility of this
approach. These data demonstrated significant expression of
the full-length polypeptide under the in vitro culture condi-
tions tested by PTC124, with the maximum effect at 5mg ml 1
concentration. Increasing the concentration of PTC124 did not
improve the read-through, which is consistent with the
findings of others (Welch et al., 2007). It should be noted
that PTC124 at this concentration resulted in only a partial
correction of the ABCC6 expression. Although the precise
level of expression of ABCC6 needed in individual patients to
prevent ectopic mineralization is currently unknown, at least
50% level, and possibly much lower, is sufficient as attested to
by the fact that heterozygous carriers of a mutation do not
develop mineralization phenotypes (Uitto et al., 2013). In
further studies, the in vivo efficacy of PTC124 can be tested in
a preclinical animal model of knock-in mice harboring human
Figure 5. The zebrafish ABCC6 messenger RNA (mRNA) rescue assay.
Injection of one- to four-cell-stage zebrafish embryos with a morpholino
targeting the abcc6a gene results in a profound phenotype consisting of
pericardial edema and curled tail at 3 days after fertilization (b), as compared
with control embryos injected with biologically inactive standard control
morpholino (a). Injection of the wild-type (WT) human ABCC6 mRNA together
with the morpholino essentially rescues the phenotype (c). Similarly, injection
of human ABCC6 mRNA harboring glycine (e) or cysteine (f) at position 1,141
reversed the morpholino-induced phenotype. However, injection of human
ABCC6 mRNA, which harbors the p.R1141X mutation, does not result in
phenotypic rescue (d).
Table 2. Zebrafish messenger RNA (mRNA) rescue
assay
Group1
Amino acid at position
1,141
No. of embryos
injected
Lethality
(%)2
Mo — 107 71.0
Scmo — 108 12.0
MoþWT Arg 96 9.4
Moþ TGA STOP 102 85.3
Moþ TGG Trp 94 26.6
Moþ TGC Cys 134 7.5
MoþGGA Gly 125 16.0
1Zebrafish embryos were injected at day 0 with an abcc6a morpholino
(Mo) alone or with human ABCC6 mRNA, either wild type (WT) harboring
arginine at position 1,141, corresponding to the p.R1141X stop codon
mutation (TGA), or containing a missense substitution of tryptophan (TGG),
cysteine (TGC), or glycine (GGA) instead of arginine at position 1,141.
Some embryos were injected with universal standard control morpholino
(Scmo).
2The number of dead embryos were counted at 24 hours after injection and
expressed as percent of the total number of embryos injected.
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ABCC6 with p.R1141X mutations in both alleles on the
Abcc6 / background.
Although PTC124 has been shown to facilitate read-through
of premature termination codons in a number of genes, the
information on the amino acid that substitutes the stop codon
is not known in case of ABCC6. It is conceivable that the
presence of such an amino acid carried by a near-cognate
transfer RNA (instead of the parent wild-type arginine in case
of p.R1141X) could be pathogenic, essentially representing a
missense mutation. To test the potential pathogenicity of such
amino acid substitutions, we have developed an innovative
zebrafish mRNA rescue system that will provide information
as to whether the amino acid substitution in ABCC6 is
pathogenic or not (Li et al., 2010, 2011). Our results
showed that substitution of arginine at position 1,141 by
cysteine, tryptophan, or glycine did not alter the functionality
of the protein. It should be noted that this innovative zebrafish
mRNA rescue system should be applicable to other proteins as
well, an issue that has not been addressed in the development
of similar pharmacologic approaches for other heritable
diseases.
PTC124 is an orally bioavailable compound that promotes
read-through of nonsense mutations demonstrated in a num-
ber of cell culture and mouse model systems (Welch et al.,
2007; Kayali et al., 2012; Peltz et al., 2013). The
pharmacokinetics and safety of this compound in healthy
adult volunteers have been documented in single-dose and
multi-dose studies, with doses ranging from 10 to 50 mg per kg
per dose twice a day for 14 days (Hirawat et al., 2007).
PTC124 administered orally was well tolerated as a single
dose up to 100 mg per kg. At higher doses, 150 and 200 mg
per kg, PTC124 induced mild headache, dizziness, and
gastrointestinal events. With multiple doses of 50 mg per kg
per dose twice a day, no significant side effects were detected,
and there was no evidence of protein elongation due to
nonspecific ribosomal read-through of normal stop codons
(Hirawat et al., 2007). Collectively, these studies suggested
that PTC124 is safe for clinical trials.
Concomitant to these initial safety studies, the efficacy of
PTC124 was tested in mouse models, including a model for
cystic fibrosis harboring the CFTR-G542X stop codon muta-
tion containing transgene (Du et al., 2008). Feeding these
mice with PTC124 resulted in the appearance of human CFTR
and restored 24–29% of its activity, i.e., cAMP-stimulated
trans-epithelial chloride transport, in comparison with wild-
type mice. These authors suggested that in light of its oral
bioavailability, safety, and toxicology profile in animal studies,
and efficacy with other nonsense alleles, PTC124 has the
potential to be an important therapeutic agent for the treat-
ment of inherited diseases caused by nonsense mutations.
Similar studies have demonstrated the efficacy of PTC124 in
promoting dystrophin production in primary muscle cells from
patients with muscular dystrophy and from mdx mice expres-
sing dystrophin nonsense alleles (Finkel, 2010; Kayali et al.,
2012). On the basis of these considerations, clinical trials have
been initiated to test the efficacy of PTC124 for the treatment
of cystic fibrosis, a disease in which B10% of the subjects
harbor a premature stop codon mutation (Wilschanski et al.,
2011). Although the study on cystic fibrosis is ongoing,
another study is currently recruiting patients with
Duchenne’s muscular dystrophy caused by premature stop
codon mutations in the dystrophin gene (see
ClinicalTrials.gov). Finally, the feasibility of PTC124-
mediated read-through of nonsense mutations in genes
associated with a number of metabolic disorders (see, e.g.,
Tan et al., 2011; Sanchez-Alcudia et al., 2012; Ho et al.,
2013), as well as in hereditary cancer syndromes (Bordeira-
Carrico et al., 2012), has been tested.
It should be noted that although PXE is considered to be a
rare disease (o200,000 affected individuals in the United
States), its estimated prevalence, B1:50,000, suggests that
there are at least 7,000 affected individuals in the United
States, and if the same prevalence is extrapolated to the global
level, as many as 150,000 individuals are affected with PXE in
the world (Uitto, 2012). Considering the fact that 100% of
patients with PXE develop angioid streaks, and the majority of
them encounter loss of visual acuity eventually leading to
blindness if left untreated, successful therapy of these patients
with PTC124 would potentially prevent blindness in
thousands of individuals worldwide. Furthermore, prevention
or amelioration of vascular complications would significantly
reduce the morbidity and mortality associated with this,
currently intractable, disorder.
MATERIALS AND METHODS
Reagents, plasmid, and site-directed mutagenesis
PTC124 (Ataluren) was purchased from Selleckchem (Houston, TX)
and dissolved in DMSO (Sigma-Aldrich, Deisenhofen, Germany) just
before use. A full-length wild-type human ABCC6 complementary
DNA linked to a nucleotide sequence encoding DDK peptide tag at
the 30 end was cloned into pCMV6-Entry expression vector purchased
from OriGene (RC211938, Rockville, MD). Using this construct as a
template, seven different ABCC6 nonsense cDNA constructs were
obtained by site-directed mutagenesis according to the manufac-
turer’s instructions (Agilent, Santa Clara, CA).
Cell culture and transfection
HEK293 cells were cultured in DMEM supplemented with 10% fetal
calf serum (Gibco BRL, Grand Island, NY), and incubated at 37 1C
under 5% CO2. Cells were transfected with different ABCC6
complementary DNA constructs using Lipofectamine 2000, as sug-
gested by the manufacturer (Invitrogen, Grand Island, NY). After
4 hours of incubation, the medium was replaced with fresh culture
medium without or with PTC124 at different concentrations. At
different time points, the cells were evaluated for the synthesis of
ABCC6-DDK fusion protein either by immunofluorescence or In-Cell
ELISA. For each construct, at least three independent transfection
experiments were performed.
Immunofluorescence
Immunofluorescence was performed on 4% paraformaldehyde-fixed
cells (15 minutes at room temperature). Nonspecific sites were
blocked for 60 minutes in 2% BSA, and cells were then incubated
overnight at 4 1C with mouse anti-DDK antibody (1:2,000, OriGene).
After three washes in phosphate-buffered saline, cells were incubated
for 1 hour with Alexa Fluor 488–conjugated goat anti-mouse
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secondary antibody. After triple washing with phosphate-buffered
saline, the cells were mounted with antifade reagent and stained with
4’,6-diamidino-2-phenylindole (Molecular Probes, Eugene, OR). The
stained cells were analyzed using a fluorescent microscope (Zeiss,
Go¨ttingen, Germany).
In-Cell ELISA
To quantify the efficiency of read-through, the treated cells in 96-well
plate were evaluated by using the Colorimetric In-Cell ELISA Kit
(Pierce Biotechnology, Rockford, IL) according to the manufacturer’s
protocol. The absorbance was measured at 460 nm within 30 minutes
of stopping the reaction. The value was normalized to corresponding
untreated controls and converted to percentage using the expression
of the wild-type ABCC6-DDK construct as 100%.
Cell proliferation assay
For PTC124 cytotoxicity assay, HEK293 cells were seeded in 96-well
plates in triplicate at a density of 2,000 cells per well and incubated
with PTC124 at concentrations from 0 to 100mg ml 1. The medium
was changed daily. At 72 hours, cell proliferation was determined by
a colorimetric assay using the CellTitCellTiter 96 Non-Radioactive
Cell Proliferation Assay Kit (MTT; Promega, Madison, WI) according
to the manufacturer’s protocol. The spectrophotometric absorbance of
each sample was measured at 595 nm using Bio-Rad microplate
reader (Hercules, CA).
Zebrafish mRNA rescue assay
To test the potential pathogenicity of missense substitutions after read-
through of ABCC6 induced by PTC124, a zebrafish mRNA rescue
assay was performed. Capped full-length human ABCC6 mRNA
corresponding to wild-type, R1141X, or putative read-through substitu-
tions of arginine1141 by cysteine, tryptophan, or glycine was
transcribed from an expression vector pCMV-Tag4B using the T3
mMessage mMachine kit (Ambion, Austin, TX). The morpholino was
injected into one- to four-cell-stage embryos either alone or in
combination with the mRNAs as above (2.4 mmol). The injected
zebrafish embryos were followed up for their phenotype and
survival rate.
Statistical analysis
The data were expressed as mean±SEM. Statistical analyses were
performed using a two-sided Student’s t-test, and statistical signifi-
cance was accepted at Po0.05.
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